Conagen Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
28
- Latest Deal Type
-
Debt - PPP
- Financing Rounds
-
3
- Investments
-
1
Conagen General Information
Description
Developer of bio-amazing synthetic biology solutions for food and beverage, nutrition and pharma industries. The company offers strain development, metabolic pathway engineering, fermentation process development, commercial-scale microbial fermentation, analytical and extraction chemistry and laboratory robotics and automation services, providing clients with the metabolic pathways of synthetic biology through specialized fermentation.
Contact Information
Website
www.conagen.comCorporate Office
- 15 DeAngelo Drive
- Bedford, MA 01730
- United States
Corporate Office
- 15 DeAngelo Drive
- Bedford, MA 01730
- United States
Conagen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Conagen Comparisons
Industry
Financing
Details
Conagen Competitors (9)
One of Conagen’s 9 competitors is Novonesis, a Corporation company based in Lyngby, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novonesis | Corporation | Lyngby, Denmark | ||||
| BioTork | Venture Capital-Backed | Gainesville, FL | ||||
| DMC Biotechnologies | Venture Capital-Backed | Boulder, CO | ||||
| GlycosBio | Venture Capital-Backed | Houston, TX | ||||
| BellBrook Labs | Venture Capital-Backed | Madison, WI |
Conagen Patents
Conagen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025137687-A2 | Production of peptides using tandem repetitive recombination strategy | Inactive | 22-Dec-2023 | ||
| WO-2025137687-A3 | Production of peptides using tandem repetitive recombination strategy | Inactive | 22-Dec-2023 | ||
| WO-2025030091-A2 | Resveratrol production from recombinant host | Inactive | 02-Aug-2023 | ||
| WO-2025030091-A3 | Resveratrol production from recombinant host | Inactive | 02-Aug-2023 | ||
| WO-2025030091-A8 | Resveratrol production from recombinant host | Inactive | 02-Aug-2023 | C12P7/22 |
Conagen Signals
Conagen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Conagen Investments (1)
Conagen’s most recent deal was a Corporate Asset Purchase with Glycoproteins production platform. The deal was made on 21-Aug-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Glycoproteins production platform | 21-Aug-2019 | Corporate Asset Purchase | Buildings and Property |
Conagen FAQs
-
When was Conagen founded?
Conagen was founded in 2010.
-
Where is Conagen headquartered?
Conagen is headquartered in Bedford, MA.
-
What is the size of Conagen?
Conagen has 28 total employees.
-
What industry is Conagen in?
Conagen’s primary industry is Biotechnology.
-
Is Conagen a private or public company?
Conagen is a Private company.
-
What is Conagen’s current revenue?
The current revenue for Conagen is .
-
Who are Conagen’s investors?
Sumitomo Chemical and Small Business Innovation Research and Small Business Technology Transfer Programs have invested in Conagen.
-
Who are Conagen’s competitors?
Novonesis, BioTork, DMC Biotechnologies, GlycosBio, and BellBrook Labs are some of the 9 competitors of Conagen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process